RecruitingPhase 3NCT05594927

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

Studying Cap myopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beijing Shenogen Biomedical Co., Ltd
Principal Investigator
Jihui Hao, MD
Tianjin Medical University Cancer Institute and Hospital
Intervention
Icaritin(drug)
Enrollment
261 target
Eligibility
18 years · All sexes
Timeline
20222025

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05594927 on ClinicalTrials.gov

Other trials for Cap myopathy

Additional recruiting or active studies for the same condition.

See all trials for Cap myopathy

← Back to all trials